To include your compound in the COVID-19 Resource Center, submit it here.

Novartis' Kisqali meets in Phase III for breast cancer in premenopausal women

Novartis AG (NYSE:NVS; SIX:NOVN) reported top-line data from the Phase III MONALEESA-7 trial in over 670 premenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers